Deborah R Taylor

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi request reprint Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets
    Miriam E R Darnell
    Laboratory of Hepatitis and Related Emerging Agents, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, CBER FDA, Bethesda, MD 20892, USA
    J Infect Dis 196:1329-38. 2007
  2. ncbi request reprint Obstacles and advances in SARS vaccine development
    Deborah R Taylor
    Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, Center for Biologics Evaluation and Research CBER, US Food and Drug Administration, Bethesda, MD 20892, USA
    Vaccine 24:863-71. 2006
  3. pmc New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1
    Deborah R Taylor
    CBER FDA, HFM 448, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol 79:6291-8. 2005
  4. pmc Persistent growth of a human plasma-derived hepatitis C virus genotype 1b isolate in cell culture
    Erica Silberstein
    Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    PLoS Pathog 6:e1000910. 2010
  5. ncbi request reprint Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products
    Miriam E R Darnell
    Center for Biologics Evaluation and Research, U S Food and Drug Administration, Bethesda, Maryland, USA
    Transfusion 46:1770-7. 2006
  6. doi request reprint Evolution of cell culture systems for HCV
    Deborah R Taylor
    Center for Biologics and Evaluation, Food and Drug Administration, Bethesda, MD, USA
    Antivir Ther 18:523-30. 2013
  7. pmc Altering SARS coronavirus frameshift efficiency affects genomic and subgenomic RNA production
    Ewan P Plant
    Laboratory of Emerging Pathogens, Division of Transfusion Transmitted Diseases, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Viruses 5:279-94. 2013
  8. pmc Achieving a golden mean: mechanisms by which coronaviruses ensure synthesis of the correct stoichiometric ratios of viral proteins
    Ewan P Plant
    Laboratory of Hepatitis and Related Emerging Agents, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, CBER, FDA, 8800 Rockville Pike, HFM310, Bethesda, Maryland 20892, USA
    J Virol 84:4330-40. 2010
  9. ncbi request reprint Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV
    Miriam E R Darnell
    Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448, Bethesda, MD 20892, USA
    J Virol Methods 121:85-91. 2004
  10. ncbi request reprint Innate immunity and hepatitis C virus: eluding the host cell defense
    Deborah R Taylor
    Laboratory of Hepatitis and Related Emerging Agents, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, CBER FDA, Bethesda, MD 20892, USA
    Front Biosci (Landmark Ed) 14:4950-61. 2009

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets
    Miriam E R Darnell
    Laboratory of Hepatitis and Related Emerging Agents, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, CBER FDA, Bethesda, MD 20892, USA
    J Infect Dis 196:1329-38. 2007
    ..Previous vaccine reports have noted robust neutralizing antibody and inflammatory responses in ferrets, resulting in enhanced hepatitis...
  2. ncbi request reprint Obstacles and advances in SARS vaccine development
    Deborah R Taylor
    Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, Center for Biologics Evaluation and Research CBER, US Food and Drug Administration, Bethesda, MD 20892, USA
    Vaccine 24:863-71. 2006
    ..Described here are issues related to progress in vaccine development and the obstacles that lie ahead for both researchers and regulatory agencies...
  3. pmc New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1
    Deborah R Taylor
    CBER FDA, HFM 448, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol 79:6291-8. 2005
    ..These results may explain successful HCV replicon clearance by IFN-alpha in vitro and may provide a promising new therapeutic strategy for HCV as well as other viral infections...
  4. pmc Persistent growth of a human plasma-derived hepatitis C virus genotype 1b isolate in cell culture
    Erica Silberstein
    Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    PLoS Pathog 6:e1000910. 2010
    ..This virus constitutes a novel tool for the study of one of the most relevant strains of HCV, genotype 1b, which will now be available for HCV life cycle research and useful for the development of new therapeutics...
  5. ncbi request reprint Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products
    Miriam E R Darnell
    Center for Biologics Evaluation and Research, U S Food and Drug Administration, Bethesda, Maryland, USA
    Transfusion 46:1770-7. 2006
    ..Effective methods for inactivating the SARS-CoV in protein solutions are described in this report...
  6. doi request reprint Evolution of cell culture systems for HCV
    Deborah R Taylor
    Center for Biologics and Evaluation, Food and Drug Administration, Bethesda, MD, USA
    Antivir Ther 18:523-30. 2013
    ..Many cell culture systems have used genetically-engineered viruses to gain growth in culture through the use of replicons, but recent advances using natural isolates may improve the outlook for progress in HCV research. ..
  7. pmc Altering SARS coronavirus frameshift efficiency affects genomic and subgenomic RNA production
    Ewan P Plant
    Laboratory of Emerging Pathogens, Division of Transfusion Transmitted Diseases, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Viruses 5:279-94. 2013
    ..The data suggest that either the RNA sequence or the ratio of viral proteins resulting from different levels of frameshifting affects viral replication...
  8. pmc Achieving a golden mean: mechanisms by which coronaviruses ensure synthesis of the correct stoichiometric ratios of viral proteins
    Ewan P Plant
    Laboratory of Hepatitis and Related Emerging Agents, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, CBER, FDA, 8800 Rockville Pike, HFM310, Bethesda, Maryland 20892, USA
    J Virol 84:4330-40. 2010
    ..The findings of these analyses all support a "golden mean" model in which viruses use both programmed ribosomal frameshifting and translational attenuation to control the relative ratios of their encoded proteins...
  9. ncbi request reprint Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV
    Miriam E R Darnell
    Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448, Bethesda, MD 20892, USA
    J Virol Methods 121:85-91. 2004
    ..We describe the kinetics of these efficient viral inactivation methods, which will allow research with SARS-CoV containing materials, that are rendered non-infectious, to be conducted at reduced safety levels...
  10. ncbi request reprint Innate immunity and hepatitis C virus: eluding the host cell defense
    Deborah R Taylor
    Laboratory of Hepatitis and Related Emerging Agents, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, CBER FDA, Bethesda, MD 20892, USA
    Front Biosci (Landmark Ed) 14:4950-61. 2009
    ..Here we review the different ways that HCV evades the immune response elicited by IFN...
  11. pmc Protein synthesis and endoplasmic reticulum stress can be modulated by the hepatitis C virus envelope protein E2 through the eukaryotic initiation factor 2alpha kinase PERK
    Nicole Pavio
    Howard Hughes Medical Institute, Department of Molecular Microbiology and Immunology, School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    J Virol 77:3578-85. 2003
    ..These findings may also explain how the virus promotes persistent infection by overcoming the cellular ER stress response...
  12. ncbi request reprint Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins
    Stephanie T Shi
    Department of Molecular Microbiology and Immunology, University of Southern California, Keck School of Medicine, Los Angeles, California 90033, USA
    Virology 292:198-210. 2002
    ....
  13. pmc Detection of a novel unglycosylated form of hepatitis C virus E2 envelope protein that is located in the cytosol and interacts with PKR
    Nicole Pavio
    Howard Hughes Medical Institute, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    J Virol 76:1265-72. 2002
    ..Thus, an ER protein can exist in the cytosol as an unglycosylated species and impair cellular functions...